You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

92 Results
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant
Drugs Used:
DOCEtaxel,
DOXOrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2016
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    daBRAfenib - In combination with trametinib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
Exceptional Access Program
    trametinib - In combination with dabrafenib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daBRAFenib,
trametinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2021
Statistical Reports
Statistical Reports
Drug
Other Name(s): Jemperli
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2025
Drug
Other Name(s): Imfinzi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2024
Drug
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2021
Drug
Other Name(s): Cerubidine®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2019
Drug
Other Name(s): Adriamycin®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Oct 2023
Drug
Other Name(s): Darzalex® SC
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2023
Drug
Other Name(s): Taxotere®
Quick Link(s):
Drug Monograph, Patient Info Sheet
May 2024
Drug
Other Name(s): Cosmegen®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2022

Pages